FrancophonIA/ELRC3.0 huggingface dataset:
English: Before starting treatment with Translarna, patients will have a genetic test to confirm that their disease is due to a nonsense mutation and that they are therefore suitable for treatment with Translarna.
Estonian: Enne ravi alustamist Translarnaga tehakse patsientidele geenitest, et kontrollida, kas nende haigus on tingitud nonsenss-mutatsioonist ja kas seega ravi Translarnaga sobib neile.
English: Translarna is available as granules (125, 250 and 1,000 mg) to be taken by mouth after mixing them with liquid or semi-solid food (such as yogurt).
Estonian: Translarnat turustatakse graanulitena (125, 250 ja 1000 mg), mis manustatakse suukaudselt pärast segamist vedela või poolvedela toiduga (nt jogurtiga).
English: Because this protein helps to protect muscles from injury as muscles contract and relax, in patients with Duchenne muscular dystrophy the muscles become damaged and eventually stop working.
Estonian: Et see valk aitab kaitsta lihaseid kokkutõmbumisel ja lõdvestumisel vigastuste eest, kahjustuvad Duchenne'i lihasdüstroofiaga patsientide lihased ja lakkavad lõpuks töötamast.
English: No improvement was seen with the higher dose (80 mg/kg daily).
Estonian: Suurema annusega (80 mg/kg ööpäevas) paranemist ei täheldatud.
English: What are the risks associated with Translarna?
Estonian: Mis riskid Translarnaga kaasnevad?
English: For the full list of side effects and restrictions of Translarna, see the package leaflet.
Estonian: Translarna kohta teatatud kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Translarna can only be obtained with a prescription and treatment should be started by a specialist doctor experienced in the management of Duchenne/Becker muscular dystrophy.
Estonian: Translarna on retseptiravim ja ravi Translarnaga peab alustama eriarst, kes on kogenud Duchenne'i/Beckeri lihasdüstroofia ravis.
English: Duchenne muscular dystrophy is rare, and Translarna was designated an ‘orphan medicine' (a medicine used in rare diseases) on 27 May 2005.
Estonian: Duchenne'i lihasdüstroofia esineb harva ja Translarna nimetati 27. mail 2005 harvikravimiks.
English: Translarna must not be used at the same time as aminoglycoside antibiotics given by injection or infusion (drip) into a vein.
Estonian: Translarnat ei tohi kasutada samaaegselt aminoglükosiidantibiootikumidega, mida manustatakse veeni süstides või infusiooniga.
English: Duchenne muscular dystrophy can be caused by a number of genetic abnormalities.
Estonian: Duchenne'i lihasdüstroofiat võivad põhjustada mitmed geneetilised anomaaliad.
English: How is Translarna used?
Estonian: Kuidas Translarnat kasutatakse?
English: Translarna is for use in patients whose disease is due to the presence of certain defects (called nonsense mutations) in the dystrophin gene which prematurely stop the production of a normal dystrophin protein, leading to a shortened dystrophin protein that does not function properly.
Estonian: Translarna on näidustatud kasutamiseks patsientidel, kelle haigus on põhjustatud düstrofiini geeni teatud defektidest (nonsenss-mutatsioonidest), mis peatavad enneaegselt normaalse düstrofiinvalgu tootmise, mistõttu düstrofiinvalk on lühem ega toimi korralikult.
English: How does Translarna work?
Estonian: Kuidas Translarna toimib?
English: Although an initial analysis of the results of all the data from the study did not show a significant difference in the distances patients in the Translarna and placebo groups could walk, further analyses indicated that walking ability worsened to a lesser extent with 40 mg/kg daily Translarna than with placebo: after 48 weeks of treatment patients receiving 40 mg/kg daily Translarna could walk on average 32 metres more than those given placebo.
Estonian: Kuigi kõigi uuringuandmete esialgse analüüsi tulemused ei näidanud Translarna uuringurühma ja platseeborühma patsientidel kõndimiskauguse olulist erinevust, osutas edasine analüüs, et kõndimisvõime halvenes Translarna 40 mg/kg ööpäevase annuse kasutamisel vähem kui platseeboga: pärast 48 ravinädalat suutsid Translarnat annuses 40 mg/kg ööpäevas saanud patsiendid kõndida keskmiselt 32 m rohkem kui platseebot saanud patsiendid.
English: The Agency acknowledged that patients with Duchenne muscular dystrophy have an unmet need for treatment of this serious condition.
Estonian: Amet märkis ka, et Duchenne'i lihasdüstroofiaga patsientide vajadus selle raske haiguse raviks ei ole täidetud.
English: A small study in children aged 2 to 5 years with Duchenne muscular dystrophy found that the usual dose of Translarna 40 mg/kg daily was sufficient.
Estonian: 2-5-aastaste Duchenne'i lihasdüstroofiaga laste väikesearvulises uuringus tuvastati, et Translarna tavapärane annus 40 mg/kg ööpäevas on piisav.
English: Translarna works in these patients by enabling the protein-making apparatus in cells to move past the defect, allowing the cells to produce a functional dystrophin protein.
Estonian: Translarna toimib neil patsientidel viisil, mis võimaldab rakkude valgusünteesi süsteemil defekti parandada, mistõttu rakud saavad toota toimivat düstrofiinvalku.
English: Duchenne muscular dystrophy is a genetic disease that gradually causes weakness and loss of muscle function.
Estonian: Duchenne'i lihasdüstroofia on geneetiline haigus, mis põhjustab progresseeruvat lihasnõrkust ja lihasfunktsiooni kadu.
English: The effect was more pronounced in a subgroup of patients whose ability to walk was worsening, where patients taking 40 mg/kg daily Translarna could walk on average 50 metres more than those taking placebo.
Estonian: Mõju oli väljendunum halveneva kõndimisvõimega patsientide alarühmas, kus patsiendid, kes võtsid Translarnat annuses 40 mg/kg ööpäevases, suutsid kõndida keskmiselt 50 m rohkem kui platseebot saanud patsiendid.
English: In one main study, involving 174 patients aged 5 to 20 years with Duchenne muscular dystrophy who were able to walk, two doses of Translarna (40 mg/kg daily and 80 mg/kg daily) were compared with placebo (a dummy treatment).
Estonian: Ühes põhiuuringus, milles osales 174 Duchenne'i lihasdüstroofiaga kõndimisvõimelist 5-20-aastast patsienti, võrreldi Translarna kahte annust (40 mg/kg ööpäevas ja 80 mg/kg ööpäevas) platseeboga (näiv ravim).
English: What benefits of Translarna have been shown in studies?
Estonian: Milles seisneb uuringute põhjal Translarna kasulikkus?
English: Patients with Duchenne muscular dystrophy lack normal dystrophin, a protein found in muscles.
Estonian: Duchenne'i lihasdüstroofiaga patsientidel puudub normaalne düstrofiin, mis on üks lihasevalkudest.
English: An overview of Translarna and why it is authorised in the EU
Estonian: Ülevaade ravimist Translarna ja ELis müügiloa väljastamise põhjendus
English: Translarna is a medicine that is used to treat patients aged 2 years and older with Duchenne muscular dystrophy who are able to walk.
Estonian: Translarna on ravim, mida kasutatakse Duchenne'i lihasdüstroofia raviks vähemalt 2-aastastel kõndimisvõimelistel patsientidel.
English: Translarna is used in the small group of patients whose disease is caused by a specific genetic defect (called a ‘nonsense mutation') in the dystrophin gene.
Estonian: Translarnat kasutatakse düstrofiini geeni spetsiifilisest geenidefektist (nonsenss-mutatsioonist) põhjustatud lihasdüstroofiaga patsientide väikeses rühmas.
English: The maximum single dose is 200 mg.
Estonian: Maksimaalne üksikannus on 200 mg.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Raptiva to Serono Europe Ltd. on 20 September 2004.
Estonian: Euroopa Komisjon väljastas Raptiva müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, ettevõttele Serono Europe Ltd. 20. septembril 2004.
English: The medicine can only be obtained with a prescription.
Estonian: Ravimit saab üksnes retsepti alusel.
English: EUROPEAN PUBLIC ASSESSMENT REPORT (EPAR) RAPTIVA
Estonian: EUROOPA AVALIK HINDAMISARUANNE RAPTIVA Kokkuvõte üldsusele
English: The Committee recommended that Raptiva be given marketing authorisation.
Estonian: Raptivale soovitati anda müügiluba.
English: How has Raptiva been studied?
Estonian: Kuidas Raptivat uuriti?
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the studies performed, to reach their recommendations on how to use the medicine.
Estonian: Selles selgitatakse, kuidas inimtervishoius kasutatavate ravimite komitee hindas teostatud uuringuid, et koostada soovitused
English: The main measure of effectiveness was the proportion of patients who ‘responded' to treatment after 12 weeks, meaning that symptom scores improved by 75% or more.
Estonian: Tõhususe peamine näitaja oli patsientide osakaal, kellel saadi 12 nädala järel ravitulemus - sümptomite skoori paranemine 75% või rohkem.
English: In the fifth study, 526 of the 793 patients were ‘high need', since they had failed to respond to or could not take other systemic treatments.
Estonian: Viiendas uuringus kuulus 526 patsienti 793 patsiendist nn uut ravimeetodit väga vajavate patsientide rühma, sest neil ei olnud teiste süsteemsete ravimitega saadud ravitulemust või ei olnud nad neid ravimeid saanud kasutada.
English: If you need more information about your medical condition or your treatment, read the Package Leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui soovite oma tervisliku seisundi või ravi osas asjakohast lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või võtke ühendust oma arsti või apteekriga.
English: The active substance in Raptiva, efalizumab, is a monoclonal antibody.
Estonian: Raptiva toimeaine efalisumab on monoklonaalne antikeha.
English: The Committee for Medicinal products for Human Use (CHMP) noted that psoriasis was more severe in ‘high-need' patients, and that the effectiveness of Raptiva is relevant for these patients.
Estonian: Inimtervishoius kasutatavate ravimite komitee märkis, et psoriaas oli raskem nn uut ravimit väga vajavate patsientide rühmas ja Raptiva tõhusus on oluline neile patsientidele.
English: Raptiva should not be used in people who may be hypersensitive (allergic) to efalizumab or any of the other ingredients.
Estonian: Raptivat ei tohi kasutada inimestel, kes võivad olla ülitundlikud (allergilised) efalisumabi või ravimi mõne muu koostisaine suhtes.
English: If you want more information on the basis of the CHMP recommendations, read the Scientific Discussion (also part
Estonian: Kui soovite lisateavet inimtervishoius kasutatavate ravimite komitee soovituste aluse kohta, lugege palun teadusliku arutelu kokkuvõtet (samuti Euroopa avaliku hindamisaruande
English: Raptiva has been studied in five main studies involving over 3,000 patients with moderate to severe plaque psoriasis.
Estonian: Raptivat on uuritud viies suures uuringus, mis hõlmasid üle 3000 mõõduka kuni raske naastulise psoriaasiga patsiendi.
English: As LFA-1 is important in helping the lymphocytes to stick to cells in the skin, efalizumab reduces the inflammation in the skin that causes psoriasis.
Estonian: Kuna LFA-1 on oluline lümfotsüütide kinnitumisel naharakkude külge, vähendab efalisumab psoriaasi põhjustavat põletikku nahas.
English: In all studies, the effectiveness of Raptiva was compared with that of placebo (a dummy treatment).
Estonian: Kõigis uuringutes võrreldi Raptiva tõhusust platseebo (näiv ravim) tõhususega.
English: Patients may inject themselves once they have been trained, if their doctor thinks that this is appropriate.
Estonian: Kui arst arvab, et see on sobiv, võivad patsiendid ennast pärast vastava väljaõppe saamist ise süstida.
English: A monoclonal antibody is an antibody (a type of protein) that has been designed to recognise and bind to a specific structure (called an antigen) that is found on the surface of cells in the body.
Estonian: Monoklonaalne antikeha on antikeha (teatud tüüpi valk), mis tunneb ära keharakkude pinnal esineva spetsiifilise struktuuri (nimetatakse antigeeniks) ja seondub sellega.
English: The most common side effects with Raptiva (seen in more than 1 patient in 10) are mild to moderate flu-like symptoms including headache, fever, chills, nausea (feeling sick), myalgia (muscle pain), and leucocytosis and lymphocytosis (increased white blood cell counts).
Estonian: Kõige sagedamad Raptiva kõrvaltoimed (kirjeldatud rohkem kui ühel patsiendil kümnest) on kerge kuni mõõduka raskusega gripisarnased sümptomid, sealhulgas peavalu, palavik, külmavärinad, iiveldus, lihasvalu, ning leukotsütoos ja lümfotsütoos (vere valgeliblede arvu suurenemine).
English: It is given as a 12-week course, with a first dose of 0.7 mg per kilogram body weight followed by weekly injections of 1.0 mg/kg.
Estonian: Esmaannusena manustatakse ravimit 0,7 mg kehamassi kilogrammi kohta, edaspidi 1,0 mg kehamassi kilogrammi kohta üks kord nädalas.
English: It should also not be used in patients who have had cancer, who have active tuberculosis or another severe infection, who have other types of psoriasis, or who have low levels of
Estonian: Ravimit ei tohi kasutada ka patsientidel, kellel on olnud pahaloomuline kasvaja, kellel on aktiivne tuberkuloos või muu raske nakkus, kellel on muud tüüpi psoriaas või kelle
English: In the fifth study, overall, 166 (31%) of the 529 patients receiving Raptiva responded to treatment, compared with 11 (4%) of the 264 receiving placebo.
Estonian: Viiendas uuringus saadi Raptivaga ravitulemus 166 patsiendil 529-st (31%), samas kui platseeboga saadi ravitulemus 11 patsiendil 264-st(4%).
English: Looking at the results of the first four studies taken together, 320 (26%) of the 1,213 patients receiving 1.0 mg/kg Raptiva per week responded to treatment, compared with 25 (4%) of the 715 receiving placebo.
Estonian: Esimese nelja uuringu koondtulemuste alusel saadi Raptiva 1,0 mg/kg annuse manustamisel üks kord nädalas ravitulemus 320 patsiendil 1213-st (26%), samas kui platseeboga saadi ravitulemus 25 patsiendil 715-st (4%).
English: Raptiva is used for the treatment of adults with moderate to severe chronic (long-term) plaque psoriasis (a disease causing red, scaly patches on the skin).
Estonian: Raptivat kasutatakse mõõduka kuni raske kroonilise (pikaajalise kuluga) naastulise psoriaasi (soomussammaspool; haigus, mis põhjustab nahale punaseid ketendavaid laike) raviks täiskasvanutel.
English: Efalizumab has been designed to bind to part of a protein called LFA-1 on the surface of lymphocytes, a type of white blood cell that is involved in the inflammation process.
Estonian: Efalisumab seondub LFA-1 valgu osaga lümfotsüütide pinnal, mis on põletikuprotsessis osalevad teatud tüüpi vere valgelibled (leukotsüüdid).
English: For the full list of all side effects reported with Raptiva, see the Package Leaflet.
Estonian: Raptiva kohta teatatud kõrvalnähtude täieliku loetelu leiate pakendi infolehelt.
English: Looking only at the ‘high need' patients in this study, 30% of those receiving Raptiva responded to treatment, compared with 3% of those receiving
Estonian: Nn uut ravimit väga vajavas patsientide rühmas saadi Raptivaga ravitulemus 30% patsientidest, samas kui platseeboga saadi ravitulemus 3% patsientidest.
English: PUVA is a type of treatment where the patient receives a medicine containing a compound called a ‘psoralen' before being exposed to ultraviolet
Estonian: PUVA on raviviis, mille korral patsiendile antakse enne ultraviolettkiirgusega töötlemist psoraleeni sisaldavat ravimit.
English: Raptiva is a powder and solvent that are made up into a solution for injection.
Estonian: Raptiva on pulber ja lahusti, millest segatakse kokku süstelahus.
English: The full EPAR for Raptiva can be found here.
Estonian: Euroopa avaliku hindamisaruande täisteksti Raptiva kohta leiate aadressil siit.
English: Therefore, the Committee decided that Raptiva's benefits are greater than its risks for the treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, or who have a contra-indication to, or are intolerant to other systemic therapies including ciclosporin, methotrexate and PUVA.
Estonian: Seetõttu otsustas inimtervishoius kasutatavate ravimite komitee, et Raptiva kasulikkus mõõduka kuni raske kroonilise naastulise psoriaasiga täiskasvanud patsientidel, kellel ei ole teiste süsteemsete ravimeetodite, sealhulgas tsüklosporiini, metotreksaadi või PUVA raviga saadud ravitulemust või kellel esinevad vastunäidustused neile ravimeetoditele või kes neid ravimeetodeid ei talu, ületab ravimi kasutamisega seotud riskid.
English: Raptiva was more effective than placebo at improving the symptoms of psoriasis.
Estonian: Raptiva vähendas psoriaasi sümptomeid tõhusamalt kui platseebo.
English: What benefit has Raptiva shown during the studies?
Estonian: Milles seisnes uuringute põhjal Raptiva kasulikkus?
English: It is used in patients who have failed to respond to or cannot take other systemic (whole-body) treatments for psoriasis, including ciclosporin, methotrexate and PUVA (psoralen ultraviolet-A).
Estonian: Seda kasutatakse patsientidel, kellel ei ole teiste süsteemsete (kogu kehale mõjuvate) ravimimeetodite, sealhulgas tsüklosporiini, metotreksaadi ja PUVA-raviga (psoraleen ja ultraviolettkiirgus A) saadud ravitulemust või kes ei saa neid ravimeetodeid kasutada.
English: Raptiva treatment should be initiated by a doctor who specialises in dermatology (the treatment of skin conditions).
Estonian: Ravi Raptivaga peab alustama dermatoloog (nahahaiguste arst).
English: It contains the active
Estonian: See sisaldab toimeainet efalisumabi
English: Therapy should only be continued in patients who have responded to treatment.
Estonian: Ravi võib jätkata vaid siis, kui ravi on andnud tulemusi.
English: The studies included patients who had not taken other treatments for psoriasis in the past, as well as those who had taken other treatments.
Estonian: Tulemused olid sarnased nii neil, kes olid psoriaasi tõttu varem kasutanud süsteemseid ravimeetodeid, kui ka neil, kes sellist ravi varem saanud ei olnud.
English: Raptiva should be used with caution in patients who have problems with their liver or
Estonian: Maksa- või neeruprobleemidega patsientidel tuleb Raptiva kasutamisel olla ettevaatlik.
English: Raptiva is given by injection under the skin.
Estonian: Raptivat manustatakse nahaaluse (subkutaanse) süstena.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Exforge HCT on 16 October 2009.
Estonian: Euroopa Komisjon andis Exforge HCT müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 16. oktoobril 2009.
English: Exforge HCT is taken by mouth as one tablet once a day, at the same time of the day and preferably in the morning.
Estonian: Exforge HCT-d võetakse suu kaudu üks tablett üks kord ööpäevas alati samal ajal, soovitavalt hommikul.
English: The full EPAR for Exforge HCT can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Exforge HCT kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: The main measure of effectiveness was the average change in the blood pressure.
Estonian: Efektiivsuse põhinäitaja oli vererõhu keskmine muutus.
English: It is available as tablets containing amlodipine, valsartan and hydrochlorothiazide in the following amounts: 5/160/12.5 mg, 10/160/12.5 mg, 5/160/25 mg, 10/160/25 mg and 10/320/25 mg.
Estonian: Seda turustatakse tablettidena, mis sisaldavad amlodipiini, valsartaani ja hüdroklorotiasiidi järgmistes kogustes: 5/160/12,5 mg, 10/160/12,5 mg, 5/160/25 mg, 10/160/25 mg ja 10/320/25 mg.
English: Because the combination of the three active substances has been in use for a number of years, the company presented studies showing that the tablet containing all three substances is absorbed in the body in the same way as the separate tablets.
Estonian: Et kolme toimeaine kombinatsiooni on kasutatud aastaid, esitas ettevõte uuringute tulemused, mis näitasid, et kolme toimeainet koos sisaldav tablett imendub organismis samal viisil kui toimeained eraldi tablettidena.
English: The CHMP therefore decided that Exforge HCT's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Exforge HCT kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: For more information about treatment with Exforge HCT, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Exforge HCT-ga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Exforge HCT.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: This is a summary of the European public assessment report (EPAR) for Exforge HCT.
Estonian: See on ravimi Exforge HCT Euroopa avaliku hindamisaruande kokkuvõte.
English: Valsartan is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a body hormone called angiotensin II.
Estonian: Valsartaan on angiotensiin II retseptori antagonist, mis blokeerib organismi hormooni angiotensiin II toime.
English: amlodipine / valsartan / hydrochlorothiazide
Estonian: amlodipiin/valsartaan/hüdroklorotiasiid
English: The CHMP noted that patients already taking the three active substances would be more likely to comply with their treatment if prescribed Exforge HCT which combines the three substances in a single tablet.
Estonian: Inimravimite komitee märkis, et patsiendid, kes juba manustavad neid kolme toimeainet, järgivad raviskeemi tõenäoliselt paremini, kui neile anda Exforge HCT-d, milles on kolm toimeainet ühes tabletis.
English: The combination of the three active substances has an additive effect, reducing the blood pressure more than the individual medicines alone.
Estonian: Nende kolme toimeaine kombinatsioonil on aditiivne toime: kombinatsioon alandab vererõhku rohkem kui toimeained eraldi.
English: Exforge HCT is a medicine that contains three active substances, amlodipine, valsartan and hydrochlorothiazide.
Estonian: Exforge HCT on ravim, mis sisaldab kolme toimeainet: amlodipiini, valsartaani ja hüdroklorotiasiidi.
English: The daily dose of Exforge HCT should not exceed 10 mg of amlodipine, 320 mg of valsartan and 25 mg of hydrochlorothiazide.
Estonian: Exforge HCT ööpäevane annus ei tohi olla üle 10 mg amlodipiini, 320 mg valsartaani ja 25 mg hüdroklorotiasiidi.
English: The three active substances in Exforge HCT are anti-hypertensive medicines that are already in use in the European Union (EU).
Estonian: Exforge HCT kolm toimeainet on Euroopa Liidus juba kasutatavad kõrgvererõhuravimid.
English: In addition, one main study was carried out in 2,271 patients with moderate to severe hypertension with the highest strength of Exforge HCT (320 mg valsartan, 10 mg amlodipine and 25 mg hydrochlorothiazide).
Estonian: Lisaks viidi läbi põhiuuring, milles osales 2271 mõõduka kuni raske kõrgvererõhutõvega patsienti, kellele anti Exforge HCT-d suurimas annuses (320 mg valsartaani, 10 mg amlodipiini ja 25 mg hüdroklorotiasiidi).
English: The most common side effects with Exforge HCT (seen in between 1 and 10 patients in 100) are hypokalaemia (low blood potassium levels), dizziness, headache, hypotension (low blood pressure), dyspepsia (heartburn), pollakiuria (abnormally frequent urination), fatigue (tiredness) and oedema (fluid retention).
Estonian: Exforge HCT kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on hüpokaleemia (vere kaaliumivaegus), peapööritus, peavalu, hüpotensioon (madal vererõhk), düspepsia (kõrvetised), pollakiuuria (ebanormaalselt sage urineerimine), väsimus ja ödeem (turse).